Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07291037 | Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations(TROPION-Lung17) | recruiting | Phase 3 | 400 | AstraZenecaINDUSTRY | 21 | Sep 4, 2026 | clinicaltrials |
| NCT07361562 | A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Cogent Biosciences, Inc.INDUSTRY | 1 | Sep 4, 2026 |
| clinicaltrials |
| NCT07613723 | A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies | recruiting | Phase 1 | 9 | Zelluna Immunotherapy ASINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07617636 | Observational Study That Will Analyse the Spread and Stratification of Lung Cancer Risk Using Artificial Intelligence(ANASTASIA) | not yet recruiting | — | 1,500 | AstraZenecaINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07640932 | Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer(LUPINE) | not yet recruiting | Phase 2 | 69 | Yonsei UniversityOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07803848 | Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status(SPACE-T) | recruiting | Phase 2 | 57 | AIO-Studien-gGmbHOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07804017 | Exhaled Breath Electronic Nose for Multi-Disease Risk Prescreening(BREATH-PAN) | not yet recruiting | — | 20,000 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Sep 4, 2026 | clinicaltrials |
| NCT03178552 | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)(B-FAST) | active not recruiting | Phase 2 / Phase 3 | 1,000 | Hoffmann-La RocheINDUSTRY | 27 | Sep 3, 2026 | clinicaltrials |
| NCT04035486 | A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)(FLAURA2) | active not recruiting | Phase 3 | 587 | AstraZenecaINDUSTRY | 21 | Sep 3, 2026 | clinicaltrials |
| NCT04699838 | Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer | active not recruiting | Phase 2 | 30 | Muhammad FurqanOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04892953 | Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy | recruiting | Phase 2 | 51 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05374603 | Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC(SOUND) | active not recruiting | Phase 2 | 47 | AstraZenecaINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05673187 | Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status(ADEPPT) | active not recruiting | Phase 2 | 68 | ETOP IBCSG Partners FoundationNETWORK | 6 | Sep 3, 2026 | clinicaltrials |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06343402 | Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | recruiting | Phase 1 | 350 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 5 | Sep 3, 2026 | clinicaltrials |
| NCT06422143 | Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | recruiting | Phase 3 | 851 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 3, 2026 | clinicaltrials |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06827132 | Observational Study Evaluate Pathology Practice Use Artificial Intelligence in Patient Suspected Lung and Breast Cancer(CASCADE) | completed | — | 603 | AstraZenecaINDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07089199 | Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study(TitAN) | recruiting | Phase 2 | 34 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07143110 | LUNG-ROLL: Treatment Patterns and Cost of Illness of Lung Cancer in Canada(LUNG-ROLL) | recruiting | — | 60,000 | AstraZenecaINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07491497 | A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC | recruiting | Phase 1 / Phase 2 | 160 | TRIANA Biomedicines, Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT07509333 | MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients | recruiting | N/A | 2,000 | West China HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802821 | A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer | not yet recruiting | Phase 3 | 556 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07802834 | Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC | not yet recruiting | Phase 2 | 42 | Stanford UniversityOTHER | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04611867 | Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)(BetterEveryDay) | recruiting | N/A | 274 | Inna Chen, MDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04913285 | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | recruiting | Phase 1 | 400 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 336 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05407168 | Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool(iDECIDE) | active not recruiting | N/A | 237 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05559645 | Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)(WU-KONG15) | recruiting | N/A | 180 | Peking Union Medical College HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05837767 | A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue | recruiting | N/A | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06043817 | First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations | recruiting | Phase 1 / Phase 2 | 345 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06049212 | Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)(TroFuse-008) | active not recruiting | Phase 1 | 30 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06333678 | A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06567015 | Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs(STX-241 FIH) | recruiting | Phase 1 / Phase 2 | 171 | Pierre Fabre MedicamentINDUSTRY | 7 | Sep 2, 2026 | clinicaltrials |
| NCT06632327 | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | active not recruiting | Phase 3 | 37 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06904365 | Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women(OvAR-Y) | recruiting | — | 11 | Washington University School of MedicineOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | recruiting | N/A | 24,000 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07027514 | A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 | 60 | Ankyra Therapeutics, IncINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07076836 | Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer | recruiting | N/A | 82 | West China HospitalOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07138755 | The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients | recruiting | Phase 2 | 35 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07180862 | A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants | active not recruiting | Phase 1 | 160 | Bio-Thera SolutionsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07216105 | FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 119 | Fate TherapeuticsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07293247 | A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment | recruiting | Phase 2 | 164 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Sep 4, 2026source: clinicaltrials